Soon, an executive named Luo Zhiwei raised his hand and said:

"Mr. Yuan, I personally think that we don't have to make difficulties in the acquisition of pharmaceutical factories, so we might as well try a different way of thinking."

Yuan Ze was curious: "Oh? What is the way of thinking? ”

Luo Zhiwei Zhengse said: "The current pharmaceutical industry, after capitalization, is still relatively open on the whole, in addition to self-research, self-production, and self-sales, you can also take the road of CXO, that is, pharmaceutical outsourcing."

In this field, the R&D outsourcing and production outsourcing of drugs are relatively mature, especially some domestic CXO leaders, who have industrialized these things.

For example, a certain Kangde has formed integrated services in the fields of CRO (pharmaceutical R&D outsourcing), CMO (pharmaceutical contract customized production) and CDMO (pharmaceutical contract customized R&D and production), which is still very trustworthy.

In order to reduce the cost of R&D and production, many start-up pharmaceutical companies are basically taking the route of outsourcing. ”

Luo Zhiwei's remarks are not nonsense, they belong to the current trend of the times.

Even in the pharmaceutical sector of Big A, the growth rate of the CXO sector has been at the forefront of the growth rate of the entire pharmaceutical industry in recent years.

It can be seen that many pharmaceutical companies are indeed taking this path.

However, Yuan Ze disagreed with this, he chuckled and said: "Pharmaceutical outsourcing is indeed very worry-free and trouble-free in the early stage, and I also know that the reputation of the leading listed companies in the big A medical service sector is still trustworthy."

But the current market landscape is changing every day, globalization is also facing disintegration, and no one knows what the future holds.

It's not good, just like the chip, I didn't master the core production and manufacturing technology, and once I was stuck by others, it would be troublesome. ”

"Mr. Yuan is right." On the side, Zhan Ping nodded when he heard this.

He himself very much agrees with Yuan Ze's point of view, although pharmaceutical outsourcing seems to be a trend at present, and many pharmaceutical companies are moving closer to this aspect.

But its biggest disadvantage is that it puts its core technology in the hands of others, or the kind that is willing to be stuffed to others.

Zhan Ping took over and said: "Manager Luo's suggestion, the starting point is correct, if our company wants to carry out the business of imitation pharmaceutical, because it does not involve core technology, and the patent has also passed the protection period, it is no problem to take the CXO route." ”

Saying that, Zhan Ping paused, and said in a deep voice: "However, at present, the drugs that our company wants to engage in are new drugs and original drugs developed by ourselves, so we must not take the CXO route."

Don't look at the convenience and hassle-free, you can even save a lot of additional costs. But as far as I know, every year there are many lawsuits that arise due to disputes over the patent of the original drug.

So, there are some things that cost and expense, it can never be saved. ”

"I completely agree with Mr. Zhan's words." Luo Zhiwei hurriedly replied, and said with a sneer: "I took it for granted just now, I didn't think it through, Mr. Yuan, Mr. Zhan, you two are farting when I think of me." ”

Yuan Ze waved his hand and said with a smile: "It's okay, if there is any point of view that can be boldly said, let's discuss it together, if it is wrong, deny it, but if it is right, then adopt it."

However, on the issue of pharmaceutical outsourcing, I have the same opinion as Mr. Zhan.

Perhaps many pharmaceutical companies think that pharmaceutical outsourcing is a general trend and can be chased, but that is someone else's business. ”

Yuan Ze restrained his smile and said solemnly: "I don't deny the role of the pharmaceutical outsourcing route in optimizing the overall pharmaceutical industry structure, but that is not the way we want to go, at least not now."

Moreover, handing over our own R&D and production links to others means that whether we can survive well or not has nothing to do with our own efforts, but depends on the conscience and agreement of others.

After all, once the stakes are big enough, there will always be someone who will dare to break the rules of the game. ”

Judging from the historical development and changes in the past few thousand years, as long as the interests are big enough, there is nothing that human beings dare not do.

tearing up the agreement, changing the order at the moment, going back on its word, ignoring the facts, and playing right and wrong...... These things can be seen often even now.

Yuan Ze didn't dare to hand over the explosive new drug of fat loss Ling, which can not only effectively reduce fat and improve diabetes, to others for OEM production, but he had to grasp it in his hands.

The current era is a good era, but it is also the era when we should be most vigilant and speculate on others with the greatest malice.

Because, the bad guys have grown up to be more disguised and smarter.

After a few words of gossip, Yuan Ze continued:

"Okay, back to the point, the new drugs we want to produce and manufacture next cannot be outsourced, and we have to firmly control them in our own hands, so we either build our own factories for R&D and production, or acquire existing pharmaceutical factories to do it.

Although investing in building a factory by yourself is the most cost-saving, the cost of time will increase greatly, and at present, time is obviously more precious for us.

Therefore, in the meantime, it is still necessary to acquire a suitable pharmaceutical factory, but if it is not possible, it is necessary to directly package and acquire a whole pharmaceutical company. ”

At this time, Zhan Ping looked at Ding Junbo and asked, "Manager Ding, tell me about the local pharmaceutical companies in Jiangcheng that are going to be packaged and sold, what are their quotations?" ”

Ding Junbo said busily: "According to the data on my side, there are a total of three pharmaceutical companies that are willing to package their main business and sell them together with pharmaceutical factories, namely Baihua Pharmaceutical, Hongbo Pharmaceutical and Chengda Pharmaceutical, with quotations of 860 million yuan, 1.25 billion yuan, and 2.38 billion yuan respectively. ”

"Tell me about their main business."

"Okay." Ding Junbo hurriedly found a document from the table, and said while reading it:

"In terms of main business, the first is Baihua Pharmaceutical, which is mainly engaged in the research and development, production, sales and medical diagnosis, gene preservation, pregnancy environment monitoring and other medical and health services of medicine and health food.

The second is Hongbo Pharmaceutical, the company's main business has two parts, the first mainly includes pharmaceutical preparations, traditional Chinese medicine decoction pieces and drug herbal medicine circulation business, the second is pharmaceutical OEM, mainly receiving all kinds of tablets, capsules and granules OEM production.

Compared with the above two companies, Chengda Pharmaceutical's main business is more extensive, covering chemical pharmaceuticals, pharmaceutical business, pharmaceutical engineering, biomedicine and other sectors, and the company's main products are vitamin products, anti-infective products, reproductive system and sex hormone products, and digestive tract products...... At present, the company has more than 50 kinds of chemical APIs, pharmaceutical intermediates and preparation products.

Mr. Yuan, this is the information about these three companies that I have collected and sorted out, you have seen it. ”

At this point, Ding Junbo hurriedly handed over the documents in his hand to Yuan Ze.

Yuan Ze looked at the information for a while, and then handed it to Zhan Ping.

After Zhan Ping finished reading it, Yuan Ze asked his opinion.

Zhan Ping replied: "Among the three pharmaceutical companies, Baihua Pharmaceutical has the lowest quotation, but from the perspective of its industrial structure and factory situation, it is the most inconsistent with the products we are going to produce and manufacture next.

In addition, Chengda Pharmaceutical has outsourced a large number of drugs, and there is only one truly self-owned pharmaceutical factory, and the output is not much, which is relatively chicken for us, and we don't need to look at it.

Therefore, I personally think that Hongbo Pharmaceutical, which is engaged in the pharmaceutical OEM business, is more suitable for our company. ”

When Yuan Ze heard this, he nodded approvingly:

"Mr. Zhan and I thought together, the original intention of us to package and acquire a pharmaceutical company was to obtain its pharmaceutical factory, and the main business was secondary.

I just looked at the business acquisition of Hongbo Pharmaceutical Company, about 80% of which come from pharmaceutical OEM, and almost all the drugs produced are tablets, capsules and granules.

This has a great degree of overlap with the fat reduction spirit that our company will produce and manufacture next, in terms of the manufacturing process in the second half. ”

Lipid-reducing this drug, once it is on the market, will be mainly marketed in capsules.

According to the information given by Ding Junbo just now, Hongbo Pharmaceutical Company has three self-owned pharmaceutical factories, which far exceed Baihua Pharmaceutical and Chengda Pharmaceutical in terms of production capacity of capsule products.

Therefore, Hongbo Pharmaceutical Company is naturally the first choice among the three pharmaceutical companies.

"But Mr. Yuan, the quotation of Hongbo Pharmaceutical Company is 1.25 billion yuan, which is not a small amount, and our company can't come up with so much money at present......," Zhan Ping reminded.

After the last time the cooperation between Yuan Ze and Kang Lei and Hu Xu ended, a full 560 million RMB was transferred to the account of Yuanlai Investment Company.

However, with the development of the company during this period, various expenses have increased sharply, and Yuan Ze has embezzled tens of millions of dollars to speculate on foreign exchange before, resulting in the current available funds in the company have almost fallen below 400 million.

If you want to buy Hongbo Pharmaceutical Company, it will definitely not be enough.

However, Yuan Ze smiled at this time: "In terms of money, you don't have to worry, I will solve it."

Mr. Zhan, you will first send someone to contact the people of Hongbo Pharmaceutical Company, talk to them well, and see if you can push the price down again.

It doesn't matter if you can't hold it down, if you can negotiate two or three installments to pay, then there is also room for buffer. ”

Zhan Ping nodded and responded, "Okay, Mr. Yuan." ”

The financial problem of acquiring a pharmaceutical company, there is really no need to worry too much.

The current Yuan Ze is no longer what it used to be, and he can't afford to worry about more than a billion RMB.

Large sums of dollars in foreign exchange accounts are not mentioned.

On the Hong Kong stock account alone, the current income brought to him by the stock of Xin Dongfang Online has exceeded 500 million Hong Kong dollars.

……

So, the next two days.

Yuan Ze's mind was on making money, and the main goal was naturally to clear Xin Dongfang Online.

According to the future trend chart in the baby warehouse, he can clearly see the future trend of Xin Dongfang Online, when the stock price reached his psychological price of 35 Hong Kong dollars, he began a long road to ship.

did not smash the plate, he still chose a gentle method of pulling up and shipping at the same time.

Finally, three days later, at 3:58 p.m. on September 8, before the Hong Kong stock market closed, Yuan Ze threw out all the chips of Xin Dongfang Online in his hand.

The average selling price was HK$35.85, and the opening price was only HK$15.8.

In other words, in this operation of Xin Dongfang Online, he earned 20.05 Hong Kong dollars per share, with a basic yield of 126.9% and a leverage ratio of four times.

In the end, after deducting all the transaction costs, he made a profit of HK $695 million in Xin Dongfang Online this time, plus the original margin, with a total principal amount of HK $833.7 million.

In addition, due to the recent strengthening of the US dollar, the Hong Kong dollar, which is pegged to the US dollar, has also begun to appreciate, and the corresponding depreciation of the RMB has been triggered.

As a result, more than half a month ago, when Yuan Ze exchanged for Hong Kong dollars, the exchange rate of RMB/Hong Kong dollar was still around 1.156.

But by this time, the exchange rate had dropped to 1.125, in other words, Yuan Ze didn't do anything with this money, and it increased by 2.68% out of thin air.

Don't underestimate this 2.68% increase, based on his principal of HK$833.7 million, it is equivalent to making more than HK$20 million for nothing.

Of course, the RMB/HKD is just a small fight, and the GBP/USD held in the foreign exchange accounts of Yuan Ze and Kang Lei is the main battlefield.

However, Xin Dongfang Online did bring Yuan Ze a lot of income this time, and the profit of 695 million Hong Kong dollars, converted into RMB, is more than 600 million.

Through DBS Bank's foreign exchange settlement business, the HK$833.7 million in Yuan Ze's Hong Kong stock account was quickly settled into 741 million RMB.

After leaving a fraction of 41 million yuan to himself, the bulk of 700 million yuan was divided into two payments and entered the account of Yuanlai Investment Company.

These two sums of money, one was used to repay the 57 million yuan borrowed by Yuan Zewen Company before, and the other was to borrow 643 million yuan to the company in the form of borrowing.

In this way, Yuan Ze and the company have formed a loan relationship, and if he embezzles money from the company in the future, as long as the financial side does a good job, it can be said that he is borrowing money or asking for accounts, rather than some illegal misappropriation.

Obey the rules, Yuan Ze understands, he can obey the rules now.

In addition to clearing the warehouse and leaving, Yuan Ze naturally did not forget to inform Ou Lin and the other women.

On the 7th, he informed Ou Lin and Su Yinuo that they could leave depending on the situation.

Due to the increase in leverage, their returns this time are more than 4 times.

Among them, Ou Lin earned 136 million yuan with a principal of 30 million, she was ecstatic, but also after the funds were available, she transferred 70 million yuan to Yuan Ze as soon as possible, and kept 66 million for herself.

In this regard, Yuan Ze did not refuse and accepted it.

Although Su Yinuo didn't make as much money as Ou Lin this time, she earned 5.5 million yuan with a principal of more than 1.2 million yuan, and she couldn't help but be overjoyed and called her rich.

As for Shen Xinyao......

……

In a fragrant, warmly furnished boudoir.

Shen Xinyao looked at the account income on the mobile phone screen, her eyes were watery, and her heart was full of joy.

When the market was closed at noon today, after receiving the news from Yuan Ze and learning that she could clear Xin Dongfang Online, she didn't say a word, directly asked for leave, returned home non-stop, and then waited for the opening.

After the market opened, she saw that the stock price was still going up, so she waited and waited, and only after it couldn't go up, did she start selling little by little.

All afternoon, she was staring at the market, and because the mood of Xin Dongfang Online was very good today, her selling position was actually very good.

On average, the selling price is more than 36 Hong Kong dollars, which is higher than Yuan Zedu.

After deducting miscellaneous expenses, her operation yield is as high as 5 times, and the profit is 11.25 million RMB.

……